Shirvan Mitchell 4

What Happened

• Shirvan Mitchell, Chief Scientific Officer and Chief Development Officer of Silexion Therapeutics Corp (SLXN), received a grant of 49,726 restricted share units (RSUs) on Feb 20, 2026. The RSUs were fully vested and immediately settled into 49,726 ordinary shares. The reported acquisition price is $0.00 (award/settlement), so no cash was paid by the insider.

Key Details

• Transaction date: 2026-02-20; Form 4 filed: 2026-02-23.
• Transaction type/code: Award/Grant (A) — fully vested RSUs immediately settled for shares (per footnote F2).
• Shares acquired: 49,726 ordinary shares at $0.00 (aggregate $0 reported).
• Shares owned after transaction: not specified in the excerpt provided in this summary (filing includes holdings information but exact post-transaction total not shown here).
• Notable footnotes:
  • F1/F4: Reported share and option counts reflect adjustments for a 1-for-9 reverse split (Nov 29, 2024) and a 1-for-15 reverse split (Jul 29, 2025).
  • F2: Grant approved by the board; RSUs were fully vested and immediately settled for underlying ordinary shares.
  • F3: Certain holdings rows are included for informational purposes only.
• Filing timeliness: Form filed three days after the transaction date (Feb 23, 2026); the filing shows the transaction and no late-filing notation is indicated in the provided details.

Context

• This was an award/settlement of RSUs (not a purchase or sale). Awards settled into shares are typically compensation for services and do not necessarily signal an insider buying or selling for investment reasons.
• Because the RSUs were fully vested and immediately settled, this reflects compensation realization rather than an exercise of options or an open-market trade.